What is the daily injection for myasthenia gravis?: A guide to ZILBRYSQ® (zilucoplan)
•
4 min read
In October 2023, the U.S. Food and Drug Administration (FDA) approved zilucoplan (brand name ZILBRYSQ®), which became the first self-administered, once-daily injection for myasthenia gravis (MG). This new treatment option offers a convenient and flexible alternative for eligible adults with generalized MG who are anti-acetylcholine receptor (AChR) antibody-positive.
